Intelligent Investor

Acrux Limited (ASX: ACR) - Share Price and Research

- Current share price for ACR : $0.059

Acrux Limited (ACR), an ASX-listed company, is an Australian drug delivery company dedicated to developing and commercialising topical pharmaceuticals products for global markets. ACR uses innovative technology to administer medicines through the skin. ACR conducts its operations in Australia, Switzerland, USA and overseas, with three marketed products including Testosterone Solution and Estradiol MDTS.

ACR General Information +

ASX Code ACR
Website http://www.acrux.com.au
Industry/Sector Pharmaceuticals
Market Cap ($M) 17
ACR Share Price $0.059
Day High $0.061
Day Low $0.059
Last Close $0.059
ACR Share Price Movement - ( No change )
Prices as at 16:40, 16 Apr 2024
+Security prices are delayed by at least 20 minutes and are indicative only.
Upsell Banner

ACR Related Research

Acrux Limited (ACR) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield
HFResult 100% 18 Aug 2015 3 Sep 2015 $0.059 $0.065 25.97%
HFResult 100% 4 Sep 2014 22 Sep 2014 $0.059 $0.065 25.97%
Result 12¢ 0% 25 Feb 2014 20 Mar 2014 $0.059 $0.065 25.97%

See all dividends from Acrux Limited (ACR) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Acrux Limited (ACR) Recent ASX Announcements

Headline Annoucement date/time+ Price at announcement+ Current price+ Price 7D Avg Gain/Loss
Launch of Dapsone 5%, Gel in the United States 3 Apr 2024 8:34AM $0.047 $0.059 $0.065 risen by 25.53%
Appendix 3Y Dobinson 5 Mar 2024 3:12PM $0.053 $0.059 $0.065 risen by 11.32%
Appendix 3Y Brumley 5 Mar 2024 3:11PM $0.053 $0.059 $0.065 risen by 11.32%
  • + Company announcements and prices are delayed by at least 20 minutes. Prices are indicative only.

See all ASX announcements from Acrux Limited (ACR) or use our ASX Announcements tool to search for announcements across all ASX-listed securities.

ACR Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2023A -$0.44 -$0.20 -95.70% 0.00 0.00 0.00% 0.0%
2022A -$9.83 -$3.50 -39.80% 0.00 0.00 0.00% 0.0%
2021A -$12.63 -$5.80 1.80% 0.00 0.00 0.00% 0.0%

ACR Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2021 A 2022 A 2023 A 2021 A 2022 A 2023 A 2021 A 2022 A 2023 A
Acrux Limited (ACR) $18M -0.9566 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Mayne Pharma Group (MYX) $592M 0.9287 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Neuren Pharmaceuticals (NEU) $2,605M 799.6667 -0.5504 0.6667 16.9858 37.7778 22.6667 0.00% 0.00% 0.00%

ACR Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 1.95 0.00
Market 0.64 16.40 1.38 1.28
Sector 1.27 21.40 1.95 0.98

ACR Directors

Name Position Start Date
Mr Michael John Kotsanis Chief Executive Officer, Managing Director 3 Nov 2014
Mr Ross Dobinson Non-Executive Chairman, Non-Executive Director 19 Mar 1998
Dr Geoffrey E.D Brooke Non-Executive Director 1 Jun 2016
Dr Timothy Oldham Non-Executive Director 1 Oct 2013
Mr Donald Charles Brumley Non-Executive Director 4 Jun 2021

Acrux Limited (ACR) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
24 May 2023 BRUMLEY, Donald Exercise Related Securities 138,187 $0.000
9 Mar 2023 BRUMLEY, Donald Buy Direct Shares 1,455,000 $0.063 $91,519.270
29 Nov 2021 BRUMLEY, Donald Buy Direct Shares 750,000 $0.119 $89,214.120

See all changes in directors' interest & trades for Acrux Limited (ACR) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

ACR Management

Name Position
Joanna Johnson Chief Financial Officer,Company Secretary

ACR Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Acrux Limited (ACR). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
31,847,134 (11.24%) Phillip Asset Management Ltd

ACR Calendar of Events

Date Event
25 February 2025 Report (Interim)
23 August 2024 Report (Annual)
23 August 2024 Report (Prelim)

FAQs about Acrux Limited (ACR)

Acrux Limited's (ACR) current share price is $0.06. This constitutes a price movement of 9.23% when compared to the share price 7 days ago and is -18.06% below ACR's 12-month high of $0.07 per share. Prices are delayed by at least 20 minutes.

Relative to the previous close share price of $0.06, Acrux Limited's (ACR) current share price of $0.06 constitutes a movement of or 0%. Acrux Limited's (ACR) share price movement is -9.23% when compared to 7 days ago and is -18.06% below ACR's 52-week high of $0.07.

Acrux Limited's (ACR) 52-week high is $0.07 which was reached on 22 Jan 2024. Relative to this, ACR's current share price of $0.06 constitutes a -$0.01 or -18.06% drop since that high of $0.07 per ACR share.

Acrux Limited's (ACR) 52-week low is $0.04 which was reached on 5 Oct 2023. Relative to this, ACR's current share price of $0.06 constitutes a $0.02 or 55.26% gain since that low of $0.04 per ACR share.

Over the last 12 months, Acrux Limited (ACR) has a daily average trading volume of 348,537 ACR shares per day.

Acrux Limited (ACR) has a current dividend yield of n/a this year. Last year's dividend yield was 0%. The dividend yield for ACR is a ratio that tells you the percentage of Acrux Limited's (ACR) share price that it pays out in dividends each year.

Acrux Limited (ACR) last dividend payment was $0.06 per share and was paid on 3 Sep 2015. This last ACR dividend included 100% franking.

Acrux Limited (ACR) will release its next Annual Report on 23 August 2024. Acrux Limited's (ACR) last annual report was released on 25 Aug 2023. Click here to view Acrux Limited's (ACR) last annual report.

Acrux Limited (ACR) is classified as Health Care. Other companies in this sector include CSL Limited (CSL), Cochlear Limited (COH), ResMed Inc. (RMD), and Fisher & Paykel Healthcare Corporation Limited (FPH).

The price-to-earnings (P/E) ratio for Acrux Limited (ACR) is 0. The price-to-earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of Acrux Limited's (ACR) share price to its earnings per ACR share.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.